N-acetyl Cysteine and Patients with Non-alcoholic Fatty Liver Disease

Ain Shams University

Status and phase: Completed; Phase 3

Conditions: Simple Steatosis Non Fatty Liver

Treatments: Drug: N acetyl cysteine with weight reduction

Study type: Interventional

Funder types: Other

Identifiers

NCT05589584

1234867

Details and patient eligibility

About

Effect of N-acetyl cysteine on markers of oxidative stress and insulin resistance in patients with Non-alcoholic fatty liver disease

Enrollment: 60 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females aged 18-60 years diagnosed with NAFLD

Exclusion criteria

• History of alcohol consumption, drug addiction or the use of medications known to precipitate steatohepatitis.
• Patients with schistosomiasis, active hepatitis B or C, autoimmune and diabetes mellitus.
• current Consumption of any antioxidant supplements and hepatotoxic drug.
• Pregnancy or lactation or expecting to get pregnant during the study.
• Medical, psychological, or pharmacological factors interfering with the collection or interpretation of study data.
• Active Cancer patients.
• Anyone having hypersensitivity to N-acetylcysteine.
• Anyone already taking N-acetylcysteine.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

intervention

Experimental group

Description:

NAC and weight reduction program

Treatment:

Drug: N acetyl cysteine with weight reduction

control

No Intervention group

Description:

weight reduction program only